These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21563997)

  • 21. Vaginal atrophy. Managing vaginal dryness and irritation.
    Mayo Clin Health Lett; 2012 Oct; 30(10):6. PubMed ID: 23133861
    [No Abstract]   [Full Text] [Related]  

  • 22. Since menopause I've been bothered by vaginal dryness. Is there something that can relieve the irritation and prevent discomfort during intercourse?
    Mayo Clin Health Lett; 1998 Feb; 16(2):8. PubMed ID: 9516366
    [No Abstract]   [Full Text] [Related]  

  • 23. MsFLASH network vaginal health trial: absence of evidence is NOT evidence of absence.
    Lukas VA; Simon JA
    Menopause; 2020 Jun; 27(6):722-725. PubMed ID: 32068684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress and prospects in treating postmenopausal vaginal atrophy.
    Winneker RC; Harris HA
    Clin Pharmacol Ther; 2011 Jan; 89(1):129-32. PubMed ID: 20944561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaginal Health: Insights, Views & Attitudes (VIVA-LATAM): results from a survey in Latin America.
    Nappi RE; de Melo NR; Martino M; Celis-González C; Villaseca P; Röhrich S; Palacios S
    Climacteric; 2018 Aug; 21(4):397-403. PubMed ID: 29741110
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Topical therapy of postmenopausal dyspareunia].
    Grio R; Mazza O; Cellura A; Zaccheo F; Giobbe C; Marchino GL; Malara D
    Minerva Ginecol; 1988 Dec; 40(12):695-7. PubMed ID: 3244441
    [No Abstract]   [Full Text] [Related]  

  • 27. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration.
    Notelovitz M
    Maturitas; 1995 Dec; 22 Suppl():S31-3. PubMed ID: 8775774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of local estrogen therapy for urogenital atrophy.
    Archer DF
    Menopause; 2010; 17(1):194-203. PubMed ID: 19602990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic image (142). A woman with persistent dyspareunia and vaginal discharge. Vaginal adenosis].
    Bais AG; Helmerhorst TJ
    Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1107. PubMed ID: 12822519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of dyspareunia secondary to vulvovaginal atrophy.
    Fantasia HC
    Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Lubrication reduces difficulties during sexual intercourse after gynecological surgery].
    Picha E
    Akush Ginekol (Sofiia); 2002; 41 Suppl 1():33-5. PubMed ID: 12412353
    [No Abstract]   [Full Text] [Related]  

  • 32. [Indications critically evaluated: hormone-domain hot flashes].
    MMW Fortschr Med; 2003 Nov; 145(46):5-8. PubMed ID: 14699822
    [No Abstract]   [Full Text] [Related]  

  • 33. What should guide our patient management of vulvovaginal atrophy?
    Shapiro M
    Climacteric; 2019 Feb; 22(1):38-43. PubMed ID: 30452294
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Postmenopausal vaginal atrophy and topical therapy with an estriol-based ointment (Colpogyn): authors' experience].
    Oliva FA; Saltarelli E; D'Antonio GD; Mazzatenta E
    Minerva Ginecol; 1991 Dec; 43(12):605-7. PubMed ID: 1819780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Lactobor Intim vaginal gel for the treatment and prevention of bacterial vaginosis].
    Malinova M
    Akush Ginekol (Sofiia); 2009; 48 Suppl 2():32-3. PubMed ID: 20380096
    [No Abstract]   [Full Text] [Related]  

  • 36. Effect of oestriol gel on dyspareunia in postmenopausal women in 2 weeks of treatment: a pilot study.
    Cuerva MJ; González SP; Lazaro-Carrasco De La Fuente J; Lopez FJ; Nieto C
    J Obstet Gynaecol; 2022 Oct; 42(7):3397-3399. PubMed ID: 35658728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
    Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J
    Menopause; 2009; 16(5):907-22. PubMed ID: 19436225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogen for vulvovaginal symptoms: how low can you go?
    Brzezinski A; Benshushan A
    Menopause; 2009; 16(5):848-50. PubMed ID: 19564805
    [No Abstract]   [Full Text] [Related]  

  • 39. Intravaginal oestrogen and progestin administration: advantages and disadvantages.
    Cicinelli E
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):391-405. PubMed ID: 17981510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical practice. Management of menopausal symptoms.
    Grady D
    N Engl J Med; 2006 Nov; 355(22):2338-47. PubMed ID: 17135587
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.